Cargando…
Extended disease-free interval of 6 years in a recurrent glioblastoma multiforme patient treated with G207 oncolytic viral therapy
BACKGROUND: Glioblastoma multiforme (GBM) is a relentless primary central nervous system malignancy that remains resistant to conventional therapy despite major advances in clinical neurooncology. This report details the case of a patient who had failed conventional treatment for recurrent GBM and w...
Autores principales: | Whisenhunt, Thomas R, Rajneesh, Kiran F, Hackney, James R, Markert, James M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918376/ https://www.ncbi.nlm.nih.gov/pubmed/27512668 http://dx.doi.org/10.2147/OV.S62461 |
Ejemplares similares
-
Oncolytic myxoma virus synergizes with standard of care for treatment of glioblastoma multiforme
por: Burton, Chase, et al.
Publicado: (2018) -
Effective Treatment of Glioblastoma Multiforme With Oncolytic Virotherapy: A Case-Series
por: Gesundheit, Benjamin, et al.
Publicado: (2020) -
EPCT-22 SAFETY AND EFFICACY OF INTRAVENTRICULAR IMMUNOVIROTHERAPY WITH ONCOLYTIC HSV-1 G207 FOR TREATMENT OF LEPTOMENINGEAL DISEASE
por: Kang, Kyung-Don, et al.
Publicado: (2021) -
Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study
por: Miller, Katherine E., et al.
Publicado: (2022) -
Immunophenotypic signature of primary glioblastoma multiforme: A case of extended progression free survival
por: Gandhi, Puneet, et al.
Publicado: (2017)